Yüklüyor......
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle a...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2815546/ https://ncbi.nlm.nih.gov/pubmed/20017885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2451 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|